But drugmakers have argued this could suck supplies out of Greece if Athens leaves the euro and prices in euro terms fall sharply. The European Association of Euro Pharmaceutical Companies, representing firms involved in this so-called parallel trade, said drugmakers were wrong to say supplies could be in jeopardy if Europe did not take such emergency...» Read More
Discussing the FDA panel on a new highly anticipated cholesterol drug, with Phil Nadeau, Cowen & Co. analyst
CNBC's Meg Tirrell reports on a key ruling by and FDA panel on a new cholesterol drug.
Ten so-called breakthrough drugs for cancers and chronic conditions will cost taxpayers big bucks.
SHANGHAI, June 9- A British corporate investigator linked to a bribery scandal in China involving drugmaker GlaxoSmithKline PLC is to be released early from a 2 1/ 2- year sentence in a Chinese jail, a source close to his family said on Tuesday. The case was intertwined with an investigation of GSK in China which rocked the country's pharmaceutical market and led...
The Swiss drugmaker, which has licensed rights to dalcetrapib to Quebec- based DalCor Pharmaceuticals, said on Tuesday it would provide a companion diagnostic for use in the Phase III study. DalCor estimates about $250 million will be needed for the project, which will be run in collaboration with the Montreal Heart Institute and will screen more than 30,000...
CNBC's Meg Tirrell reports the FDA meets today and tomorrow to discuss and vote on recommendation for approval of new cholesterol drugs, Praluent and Repatha.
A woman carrying an extreme form of tuberculosis enters the country, traveling to at least three states before seeking medical treatment, reports CNBC's Meg Tirrell.
AMSTERDAM, June 8- Executives at Israeli drugmaker Teva sent an open letter to takeover target Mylan on Monday, saying they remain committed to a deal and reiterated that Teva's $40 billion takeover proposal would benefit shareholders of both firms. In the letter, addressed to Mylan executive founder Robert Coury, Teva CEO Erez Vigodman and Chairman Yitzhak...
John Studzinski, vice chairman of Blackstone Group, tells CNBC that the healthcare sector is set for more consolidation.
*Deal gives Cardinal Health more generic volume. June 5- Cardinal Health Inc said it would buy privately held drug distributor Harvard Drug Group for $1.12 billion to boost volumes of its generic distribution business. The Livonia, Michigan- based Harvard Drug Group, a distributor of generic and over-the-counter drugs, had revenue of about $450 million in 2014,...
June 5- Orexigen Therapeutics Inc and partner Takeda Pharmaceutical Co Ltd said they had filed a lawsuit against Actavis Plc to block a generic version of diet-pill Contrave. The lawsuit, filed at a Delaware district court, alleges that Actavis has infringed patents on Orexigen and Takeda's weight-loss treatment. Actavis and Teva Pharmaceutical Industries...
CNBC's Meg Tirrell reports on the woman's libido drug.
June 5- Cardinal Health Inc said it would buy privately held drug distributor Harvard Drug Group for $1.12 billion to expand its customer base and bolster its generics business. The Harvard Drug Group is a distributor of generic and over-the-counter drugs. The Harvard Drug Group had revenues of about $450 million in 2014, Cardinal health said in a statement.
An FDA panel votes to approve a pill to improve female libido.
David Hung, CEO of Medivation, explains how their prostate cancer drug, Xtandi, turned their company around.
CNBC's Meg Tirrell reports on the backing of a female libido drug. The FDA panel says risk management must go beyond labeling.
Vamil Divan, senior analyst at Credit Suisse, explains why Bristol-Myers could benefit the most from the immune-oncology trend that's emerging in pharmaceuticals.
The USDA has been developing a vaccine against bird flu and was weighing whether to release it to drug makers for widespread production. Turkey producers in Minnesota, where nearly 9 million birds have been affected by the disease since the beginning of the year, had asked the USDA to approve use of a vaccine to help prevent further infections.
Teva is poised to raise its stake in Mylan as it pursues its takeover bid. - Reuters
Teva Pharmaceutical is looking to buy more shares in Mylan, positioning itself for a possible legal challenge to the generics drugmaker.